🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check out our latest work from Common Sense Oncology! We detail essential principles for the design, analysis, and reporting of phase 3 randomised clinical trials, trying to make sure our trials are designed and reported in a patient-centered way. Time to get to work! #CSO

Our CSO RCT checklist is being covered by several media. This Twitter thread will share the links to media coverage of our RCT checklist. First, a conversation with our patient advocate Rachel Koven, and the senior author of the paper Prof. Ian Tannock in CBC News The Current

Join CSO for our upcoming journal club on Wednesday February 12th at 8:00 pm EST as we discuss the STARGLO and SWOG S1826 trials, and their applications to the treatment of lymphomas.   Link to register: queensu.zoom.us/meeting/regist…   This event will be exclusive to CSO members, so if

Don’t forget to register! It’s happening this Wednesday.

In your opinion, what is the most promising clinical trial option open for p53 mutated AML? #leusm #aml

LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML. Come listen to Bernie Marini Anthony Perissinotti Charlie Foucar and Anand Patel nerd out! #leusm #gemtuzumab #aml creators.spotify.com/pod/show/wolve…

CSO Webinar announcement! 📣 Register today! Join Dr. Anuradha Vasista and Dr. Deme Karikios as we talk about discussing prognosis with patients living with advanced cancers. The webinar will take place on Zoom on March 19th at 7:00 pm Australian Eastern Daylight Time (8:00 am

Ever been invited as a discussant to a plenary trial and wished you had a checklist to correctly and objectively appraise the clinical trial to enable the audience put things into correct perspective? Well, Common Sense Oncology has just published a checklist to help you do just that! We

Presenting at a national conference in the future? Check out our latest paper from Common Sense Oncology !

What is the best treatment for high-risk APL? Are GO-based regimens better than APML4-style? 🤔 Check out our FIRST major multi-center hematology PharmD pub and find out! 👀 #leusm #apl #HEROconsortium onlinelibrary.wiley.com/doi/10.1002/aj…

Check out are latest episode, with a star-studded cast! 🤩 "Dex and the Cytokine City: Managing CRS with Bispecifics" #leusm #lymsm #myeloma #TwitteRx @berninini James Davis, PharmD, BCOP Victoria Nachar Anthony Perissinotti Justine Preedit creators.spotify.com/pod/show/wolve…

Maintenance Therapy in AML: A Trailblazing Slam Dunk, or a Flagrant Fowl. Always a pleasure to hear Anthony Perissinotti Bernie Marini. What a lively and engaging debate! #HOPA2025

Happy to share that two Common Sense Oncology projects have been accepted for poster presentation at #ASCO25 Looking forward to discussing our findings 😊

Hi PHOO, I just sent you a detailed email response. Thank you for asking this very important question, which affords me the opportunity to offer one of my trademark antibiotic rants. Oooh, feels good, haven't done one of these in a while! Ok...strap in, here we go...

Multicenter retrospective evaluation of treatment for high risk acute promyelocytic #leukemia: Comparison of the APML4 and ATRA+ATO+GO in high risk #APL conducted by the HERO Consortium Free access: doi.org/10.1002/ajh.27… #LeuSM Bernie Marini #HemOnc

Check out our first VIDEO episode! 📽️ "CSO Encore Video Presentation - SWOG1826 & STARGLO Trials Critically Examined" Bernie Marini Anthony Perissinotti Tycel Phillips open.spotify.com/episode/3UaSRy…

Many important questions to answer: Were increased deaths on Ibr monoRx arm vs I+V due to CLL or not? Is A/Z+V similarly better than A/Z monoRx or does this speak to Ibr monoRx being subpar to A/Z monoRx? Did these patients have R/O+V or other modern 2L options available?

🔔We had to convene an emergency meeting with David Russler-Germain, MD/PhD and Manni Mohyuddin just for this episode ‼️ "ODAC - Our Decisions Are Confusing" Anthony Perissinotti Bernie Marini creators.spotify.com/pod/show/wolve…

So far, every single abstract I’ve listened to at #EHA25 reporting a clinical trial has claimed the study drug was “well tolerated” - despite patients discontinuing therapy due to AEs. One speaker said “well tolerated” >10 times. It’s meaningless. Let data speak for itself.

Some BIG practice changes happening in AML consolidation! Check out are latest episode, "Spilling Drinks over Cytarabine Dosing". Press play and hang on to your drinks everyone Anthony Perissinotti Bernie Marini 🍻creators.spotify.com/pod/profile/wo…